ESR1 and cardiovascular disorder: The most important clinical successes achieved in the ER ligand field over the past decades mainly involve SERMs or ERα antagonists which are used in the treatment of estrogen-related cancers such as breast cancer, osteoporosis, and cardiovascular diseases [47].